Biogen Inc. (BIIB) stock analysis

BIIB · Biogen Inc.

Latest recorded price: USD 251.65

Model-estimated fair value: USD 145.53. This assumption-based estimate is for general research and is not investment advice.

Sector and industry: Healthcare · Drug Manufacturers - General

At $251.65, BIIB trades 72.9% above the model's base-case value of $145.53. Using Operating FCFF DCF (revenue x margin - reinvestment), the model estimates $106.54 in the conservative case and $187.47 in the optimistic case, with a valuation confidence score of 75/100. About 74% of the value comes from the terminal value, so the result is sensitive to long-term growth and discount-rate assumptions. Fiscal 2025 figures: revenue growth -0.9%, free cash flow margin 20.7%, ROIC 5.1%. The model flags 1 risk signal for this company.

Similar companies in Healthcare